Published • loading... • Updated
Keytruda: How Merck's Pembrolizumab Became the Best-Selling Cancer Drug of All Time (Part One) | Approved with Alex Kesin and Matthew Pech
Summary by Podcast Notes
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Keytruda: How Merck's Pembrolizumab Became the Best-Selling Cancer Drug of All Time (Part One) | Approved with Alex Kesin and Matthew Pech
Keytruda (pembrolizumab) reshaped modern oncology treatment and generated $31.7 billion of revenue in 2025 alone. However, it didn't become the best-selling cancer drug of all time overnight. Part one of this Podcast Notes Premium Series explains why immunotherapies were blackballed by big pharma for almost 100 years, how scientists discovered that the immune system can be driven like a racecar, why you should never ignore a serendipitous discov…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
